The Lancet sub-issue: Auxiliary treatment of type 1 diabetes Dagly net beneficial kidney function

"This is the first study to show that complementary treatment based on insulin can reduce kidney complications," said one of the study's authors, Dr. Johan Jendle of the University of Erebro in Switzerland.
this may affect the treatment of many patients.
high blood sugar can put pressure on the kidneys, and chronic kidney failure is an important problem, patients suffering, treatment costs are high.
" Screenshot Source: The Lancet Diabetes and Endocrinology In People with Type 2 Diabetes, Daglyn has shown kidney protection.
in DEPICT-1 and DEPICT-2 trials, Dagledge has also been shown to be an insulin-assisted treatment for people with type 1 diabetes with poor blood sugar control.
a second post-mortem analysis of DEPICT trial data to further explore the effects of Dagly net on kidney function in patients with type 1 diabetes.
DEPICT trial, patients were grouped 1:1:1 and received a net 5 mg or 10 mg or placebo on the basis of insulin therapy for up to 52 weeks.
this analysis included 251 people with type 1 diabetes who had proteinuria at the baseline of the study.
At the 52nd week, the urinary albumin/creatinine ratio (UACR) was improved in patients in both dose groups, with a decrease of 13.3% and 31.1% in the 5 mg and 10 mg groups, respectively, compared to the placebo.
difference in renal cystic filtration rate (eGFR) in three groups of patients.
the proportion of patients with adverse events and severe adverse events in each treatment group was similar, with 1% and 4% of patients in the Dalgar net 5 mg group and 10 mg group having diabetic ketosis, respectively.
3 per cent, 5 per cent and 6 per cent of the placebo group, dagly net 5 mg and 10 mg group, respectively.
, no new safety signals were found.
" these side effects are consistent with previously reported in people with type 2 diabetes.
not much, our goal is to use the possible low dose to avoid potential side effects.
," Dr. Johan Jendle points out.
because the results are a re-analysis of existing data, rather than a pre-set endpoint for the original trial, the team plans to conduct a forward-looking randomized clinical trial to confirm the findings.
References . . . Per-Henrik Groop, et al., (2020). Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the PROCESS randomized controled trials. The Lancet Diabetes and Endocrinology, DOI: a glucose-lowering drug can protect kidneys in type 1 diabetes patients. Retrieved October 30, 2020, from